Ethnic Differences in the Inflammatory Response in Systemic Inflammation
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- neutrophil counts
研究概览
简要总结
The purpose of this study is to investigate putative ethnic differences in the proinflammatory response in human endotoxemia.
详细描述
Recent data show that there are significant disparities among genders and races in the incidence of sepsis. While men are consistently more likely to have sepsis than women, the apparent racial disparities are even more striking, approaching a doubling of the risk for sepsis among Afro-Americans. Most prominent is the risk among black men, the group in which sepsis occurs at the youngest age and results in the most deaths. Potential mechanisms for heterogeneous susceptibility to sepsis include genetic differences, which have been explored according to sex but not according to race, and other social and clinical factors.
The goal of this study is to explore whether proinflammatory and procoagulant responses in a well standardised inflammation model are comparable in healthy Caucasian and African volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Ect
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent obtained before any trial-related activities. (Trial activities are any procedure that would not have been performed during normal management of the subject).
- •Men aged >18 and <40 years
- •Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- •Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant
排除标准
- •Treatment with an investigational drug within three weeks prior to this trial
- •Participation in an LPS trial within the last 6 weeks
- •Hereditary deficiency of protein C or S, or a mutation of FV (Leiden), or any other known abnormality affecting coagulation, fibrinolysis or platelet function
- •History of cardiovascular disease
- •Liver or kidney dysfunction
- •Regular use of medication or alcohol abuse
- •Use of any medication within three weeks prior to the first trial day
- •Symptoms of a clinically relevant illness in the 3 weeks before the first trial day
- •Excessive sporting activities
- •Weight over 95 kg
结局指标
主要结局
neutrophil counts
IL-8
G-CSF
次要结局
- various inflammation and coagulation parameters
- Platelets
- Adverse events